Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

S'inscrire

TEVA Teva Pharmaceutical Industries Ltd

16,81

0,00 (0,00%)

Avant marché

Dernière mise à jour : 12:17:06

Retardé de 15 minutes

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024

Plus de graphiques de la Bourse Teva Pharmaceutical Indu...

Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024

Plus de graphiques de la Bourse Teva Pharmaceutical Indu...

Actualités Teva Pharmaceutical Industries Ltd

Teva to Present at the Jefferies London Healthcare Conference
Vendredi 8 Novembre 2024 ( il y a 2 semaines) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mercredi 6 Novembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Form 8-K - Current report
Mercredi 6 Novembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
Mercredi 6 Novembre 2024 ( il y a 2 semaines) • GlobeNewswire Inc.

U.S. Index Futures Surge on Trump Victory Prospects; Commodities Slide Amid Dollar Strength
Mercredi 6 Novembre 2024 ( il y a 2 semaines) • IH Market News

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
Vendredi 1 Novembre 2024 ( il y a 3 semaines) • GlobeNewswire Inc.

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as R
Vendredi 1 Novembre 2024 ( il y a 3 semaines) • GlobeNewswire Inc.

Teva Statement on European Commission Decision; Company to Appeal
Jeudi 31 Octobre 2024 ( il y a 3 semaines) • GlobeNewswire Inc.

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Mardi 22 Octobre 2024 ( il y a 4 semaines) • GlobeNewswire Inc.

BP Signals Rising Net Debt; Tesla Slumps; Stellantis CEO Announces Retirement; Berkshire Trims BofA Stake, and More
Vendredi 11 Octobre 2024 ( il y a 1 mois) • IH Market News

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
Mardi 8 Octobre 2024 ( il y a 1 mois) • GlobeNewswire Inc.

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
Jeudi 3 Octobre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Plus d'articles sur Teva Pharmaceutical Industries Ltd

Cie de SaintGobain

Societe Generale

Lvmh Moet Hennessy Louis...

Credit Agricole

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales